Skip to main content

Venture the Path Less TraveledTM

A healthcare venture capital firm rooted in the Midwest

Arboretum Ventures icon

Improving patient outcomes, reducing healthcare costs

Our progressive strategy of investing in under-ventured geographies and sectors, coupled with our expertise in building deep relationships with entrepreneurs, executives, and investment partners across the healthcare industry, are significant factors contributing to our success.

View our portfolio
medical devices icon
Medical Devices
life science tools icon
Life Science Tools
& Diagnostics
tech-enabled care delivery icon
Care Delivery
pharma adjacencies icon


We seek innovations that solve (big) healthcare problems and make a transformational impact from teams who are diverse in thought, geography, and demographics.


We have a proven formula for identifying early-stage startups that can create value in a capital-efficient manner, accelerate portfolio value, and deliver superior returns.

Portfolio Spotlight

We invest in today’s ideas to forge a path for better healthcare tomorrow

Where NeuMoDx started?
Molecular diagnostics is one of the fastest-growing segments within the in-vitro diagnostics market, but existing systems are expensive, complex, and lack sophisticated automation. Through a unique combination of automation and microfluidics, the NeuMoDx Molecular clinical PCR systems offer best-in-class ease of use, throughput, and cost per test.

Where NeuMoDx is today?
Arboretum collaborated with the team to set the strategic direction that helped accelerate the company’s product development timeline and helped recruit new investors. Since Arboretum’s investment, NeuMoDx gained regulatory approvals for its first assays, launched its product, and in September 2020, QIAGEN acquired NeuMoDx to strengthen its portfolio of automated molecular testing.

Ready to grow with us?
laboratory scientists
NewMoDX logo

We fuel the future of healthcare

under management across six funds
of the portfolio invested in under-ventured markets over 20 years
of all active companies have either a female / minority CEO or founder
patient - lives impacted
View portfolio

Shifting the venture capital paradigm

We are proud to be a Midwest venture capital firm operating with transparency, integrity, and approachability to help you realize your entrepreneurial and investor goals. Together, we’ll positively impact patients, communities, and healthcare.

Meet your team
Arboretum Ventures Senior Team


I’ve worked with many venture capital investors over my career, but Tom Shehab and the team at Arboretum Ventures are more than investors; they're proactive, involved partners. They collaborate with us, leaning in to tackle challenges shoulder to shoulder. Their steady devotion and vast network have been catalysts for our growth in advancing neuromodulation for autoimmune diseases.

Heather SimonsenCEO – Boomerang Medical

Dan Kidle and the Arboretum team have exhibited profound dedication to nurturing our company's growth as we seek to revolutionize care for critically ill patients. Their involvement extends beyond just friendly advice; they are integral to our strategic decision-making process, offering invaluable insights, guidance, and connections.

Joe EiblCEO – Flosonics Medical

Jan is a leading advocate for innovations in healthcare across our world. Her focus and dedication to enable innovation in medical devices in particular, have had great impacts in human lives across various disease states. At Koya, as we focus on transforming venous and lymphatic care, having Jan not only invest through Arboretum but also provide her counsel, advocacy, and wisdom has greatly enabled our path forward. I am personally grateful for Jan’s support and strength that any founder or CEO would desire.

Andy Doraiswamy PhDCEO – Koya Medical

Beyond providing growth capital, Tim Petersen and Arboretum Ventures have quickly become an indispensable partner to Convergent Dental. Their contributions range from Tim’s thoughtful leadership on our board to making their impressive advisory board available to me to gain their insights on a variety of strategic topics. In fact, following a recent presentation to their advisory board, one of the members made himself available for a 1:1 mentoring discussion that materially influenced a recent transaction that are in the process of completing.

Rob GershonCEO – Convergent Dental

Paul McCreadie and the Arboretum team bring a solid foundation of investing experience and a deep network of industry partners that have helped shape our development strategy at Allay. I can rely on his consistent support and thoughtful approach to board discussions whether things are going well or if we are facing challenges.

Adam GridleyCEO – Allay Therapeutics

In the News

June 17, 2024 in Home Page, News Page, PAK BioSolutions

PAK BioSolutions Raises $12 Million Series A to Expand Continuous Biomanufacturing Product Line

Today, PAK BioSolutions announced that it has raised $12M from Arboretum Ventures, BroadOak Capital Partners, and other investors to expand commercial and product development efforts for its line of automated…
Read More
May 3, 2024 in Arboretum, Home Page, News Page

Arboretum Ventures Managing Partner Tom Shehab, MD Joins the NVCA Board of Directors

The National Venture Capital Association recently announced the appointment of eight new directors to its board who will serve four-year terms from 2024-2028.
Read More
April 24, 2024 in AtaCor Medical, Home Page, News Page

AtaCor Medical Closes $28M Series C Financing to Deliver Next Generation Extravascular ICD and Pacing Options for Cardiac Rhythm Management

AtaCor Medical Inc., a privately-held medical device company delivering the next generation of extravascular leads to advance the care of cardiac rhythm management (CRM) patients, announced today that it has completed a $28M Series…
Read More